anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lenz-Majewski hyperostotic dwarfism (LMHD) is a rare condition characterized by intellectual disability, sclerosing bone dysplasia, dysmorphic facial features, brachydactyly, symphalangism and cutis laxa. Nineteen cases have been reported in the literature so far, eleven of them with PTDSS1 mutations. Although studies have had clinically similar findings, in some cases the authors have reported even rarer features such as hydrocephalus, facial paralysis, and cleft palate. We, hereby, report the case of the first patient with Lenz-Majewski syndrome (LMS) with molecular confirmation from Turkey. Although our patient had characteristic features described in the literature, she also had immunodeficiency, which has not been reported before. Although there is no established phenotype-genotype correlation, molecular mechanisms can be explained with the reporting of more patients.
Influenza virus infections result in major health and economic burdens worldwide. The World Health Organization estimates that the average global burden of interpandemic influenza is approximately 1 billion cases of influenza, from 3 to 5 million cases of severe illness, and from 300 000 to 500 000 deaths annually. Arbidol (Umifenovir) is currently licensed for the treatment and prevention of influenza in Russian Federation. Arbidol (Umifenovir) has a direct antiviral effect. Arbidol (Umifenovir) belongs to fusion inhibitors; it interacts with the virus hemagglutinin and thus prevents fusion of the viral envelope with cell membranes. The aim of the study is to obtain additional data on safety and therapeutic efficacy of investigational product Arbidol (Umifenovir) in patients with a diagnosis of influenza and common cold. Furthermore, study of viral resistance in patients with seasonal influenza infection treated with Arbidol (Umifenovir) will be performed.
This is an open-label (patients will know the names of the study drugs they receive), randomized (patients will be assigned by chance to receive 1 of 2 treatment schedules with trabectidin) study designed to examine the the survival, safety, and pharmacokinetics (blood levels) trabectedin when administered to patients with 2 types of cancer (Liposarcoma or Leiomyosarcoma) who have received treatment with other anti-cancer therapy (Anthracycline and/or Ifosfamide). Trabectedin (also referred to as Yondelis) is a drug being developed to treat patients with cancer. Yondelis will be administered intravenously (i.v.) via a central catheter (tube) into a central vein once a week (0.58 mg/m2 as a 3-hour infusion on Days 1, 8, and 15 of each 28-day treatment cycle) or once every 3 weeks (1.5 mg/m2 administered as a 24-hour infusion on Day 1 of every 21-day treatment cycle) until disease progression. Patients in each arm will be pretreated with 20 mg of dexamethasone i.v. 30 minutes prior to each infusion.
BACKGROUND: Cardiopulmonary exercise testing (CPET) is a preoperative risk stratification tool providing an objective measure of fitness and functional capacity. There is however little evidence on the use of this compared to non-physiological test in vascular surgery despite its current use. This study investigates whether CPET perioperatively has value alongside non-physiological testing for patients undergoing elective open abdominal aortic aneurysm (AAA) repair.
METHOD: Retrospective data was collected at 2 vascular centres between 2015-2019 in a CPET centre vs non-CPET centre in patients undergoing elective AAA repair. Outcomes measured included: length of stay in an intensive care unit (ICU); total length of stay; post-operative complications and acute kidney injury (AKI). Statistical analysis was performed using IBM SPSS software.
RESULTS: There were 38 patients at each centre. The mean duration of stay in ICU for patients in CPET centre was 2.5 ± 2.13 days whilst in non-CPET centre it was 3.68 ± 4.08 days (P = 0.05). The mean duration of stay in ICU and total length of stay was significantly shorter in CPET centre (P = 0.05 and P = 0.015 respectively). Mortality in CPET centre was 2.63% and 5.26% in non-CPET centre (not significant). The number of patients developing AKI post-operatively was 13.61% in CPET vs 28.95% in non-CPET centre.
CONCLUSION: CPET tested patients have statistically significant lower length of total and ICU stay compared to non-CPET patients. CPET is therefore a useful adjunct in selecting patients for open surgery compared to non-physiological testing. This study provides some evidence on the use of this routinely but not validated assessment tool in aortic aneurysm repair.
The invention discloses a production method of a silk quilt used for nourishing and protecting the kidney, and relates to health products, in particular to a production process of a novel silk quilt used for nourishing and protecting the kidney. Firstly, grifola umbellata, tuckahoe, oriental water plantain, plantain herb, loosestrife, Chinese lobelia, Chinese yam, moutan bark and prepared rehmannia root are decocted with water and then filtered to get a Chinese herbal medicine solution, silk wadding is added with a swelling agent, a silk softening agent and the Chinese herbal medicine solution, dried and cured to obtained the silk wadding containing the solution. The healthcare silk quilt of the invention has the same appearance as the existing silk quilts, and has the characteristics of the original mulberry silk quilts. Silk fiber has high rebound elasticity, bulking property, softness, strong gas permeability and moisture permeability, therefore, the silk quilt does not easily store scurf and produce acarid, does not absorb dust and avoids fiber penetration. As the Chinese herbal medicine solution is added, the silk quilt with recuperation and treatment function which is made by unique technical method can regulate the microcirculation of body. The silk quilt with the flavor of the Chinese herbal medicines is more beneficial to be absorbed by the body, can help reach the effects of nourishing and protecting the kidney by long-term use.
All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.
Endometrial carcinoma (EC) is the sixth most common cancer in females. Most ECs are detected in stage 1 and have a 5-year survival rate of more than 90%. Recurrence rates are highest within 5 years after treatment and are exceptionally rare after 10 years. Here, we describe a woman in her late 70s with endometrial cancer who was treated in 2008 and was diagnosed with a relapse in her left lung in 2023. Due to her advanced age and comorbidities, she was deemed inoperable. However, she received sequential chemotherapy and radiotherapy with a good partial response. She has now been started on hormonal therapy with an alternate megestrol and tamoxifen regime. There is a lack of follow-up imaging guidelines to detect late relapse, a dilemma in preferred treatment sequencing at relapse and an enigma in selecting chemotherapy or hormonal therapy.
The present invention relates to a terazosin hydrochloride drop pill and a preparation method thereof. The drop pill is formed by combining terazosin hydrochloride and basal materials by weight proportion of 0.5-10 to 39.5-30, wherein the basal materials are one kind or two kinds of polyethylene glycol 6000, polyethylene glycol 4000, polyethylene glycol 2000, polyethylene glycol 1500, polyethylene glycol 1000, poloxamer and span 40. The terazosin hydrochloride drop pill of the present invention is formed by solid dispersion technology. Compared with tablets, the dosage of auxiliary materials of the present invention is relatively reduced. Therefore, the present invention can be dissolved and absorbed in body fluid rapidly and can take effect quickly. The biological availability of the present invention is high and the stability is good. Moreover, because the volume of the pill is small, the pill not only can be swallowed, but also can be kept in mouth. The present invention can be carried conveniently. Therefore, the present invention is particularly suitable for old people, sickbed patients and dysphagia patients to take. The technology of the method of the present invention and the production equipment are simple. The present invention has low production cost and is suitable for large-scale production and preparation.
NEW MATERIAL:An interferon-beta-production promoter having 550000-650000 molecular weight, 1.5(mug/ml) sugar content, 4.0(mug/ml) protein content, 0.4 ratio of (sugar/protein) and 168 (IU/mug sugar) specific activity. USE:A food component having a high safety and a biophylaxis effect. PREPARATION:For example, cow's milk is fermented using Yeast kefir (Russian type YK-1) and the resultant product is freeze dried to prepare p-dery kefir. The resultant powdery kefir is extracted using 10mM sodium phosphate buffer solution (pH7.0) and the extracted solution is subjected to gel filtration to collect an active fraction. The obtained active fraction is then subjected to ion-exchange chromatography using a weak anion-exchange column resin and the adsorbates are eluted using 50mM NaCl. The eluted fraction is concentrated and then subjected to gel filtration, thus obtaining the objective interferon-beta production promoter having 550000-650000 molecular weight.
Chronic pain is a prevalent condition with enormous economic burden. Opioids such as tramadol, codeine, and hydrocodone are commonly used to treat chronic pain; these drugs are activated to more potent opioid receptor agonists by the hepatic CYP2D6 enzyme. Results from clinical studies and mechanistic understandings suggest that CYP2D6-guided therapy will improve pain control and reduce adverse drug events. However, CYP2D6 is rarely used in clinical practice due in part to the demand for additional clinical trial evidence. Thus, we designed the ADOPT-PGx (A Depression and Opioid Pragmatic Trial in Pharmacogenetics) chronic pain study, a multicenter, pragmatic, randomized controlled clinical trial, to assess the effect of CYP2D6 testing on pain management. The study enrolled 1048 participants who are taking or being considered for treatment with CYP2D6-impacted opioids for their chronic pain. Participants were randomized to receive immediate or delayed (by 6 months) genotyping of CYP2D6 with clinical decision support (CDS). CDS encouraged the providers to follow the CYP2D6-guided trial recommendations. The primary study outcome is the 3-month absolute change in the composite pain intensity score assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) measures. Follow-up will be completed in July 2024. Herein, we describe the design of this trial along with challenges encountered during enrollment.
The invention relates to a traditional Chinese medicine composition for treating chicken kidney swelling. The traditional Chinese medicine composition is prepared from Poria cocos, rhizoma alismatis, cassia twig, liquorice, grifola, bighead atractylodes rhizome, monkshood and fresh ginger. The traditional Chinese medicine composition can be powder. The method comprises the following preparation steps: (1) weighing the following various traditional Chinese medicines according to the formula amount: 20-40 parts of Poria cocos, 20-40 parts of rhizoma alismatis, 20-40 parts of cassia twig, 20-40 parts of liquorice, 20-40 parts of grifola, 20-40 parts of bighead atractylodes rhizome, 20-40 parts of monkshood and 20-40 parts of fresh ginger; (2) grinding the traditional Chinese medicines, and screening through a 20-40-mesh sieve; (3) mixing the medicines for 10-20 minutes, thereby obtaining traditional Chinese medicine powder; and (4) separately packaging the traditional Chinese medicine powder according to the weight of 100-200g per bag, thereby obtaining the finished product. The traditional Chinese medicine composition disclosed by the invention can be used for effectively treating chicken kidney swelling, and the cure rate is over 95 percent. The composition has the effects of clearing damp and inducing diuresis and warming heart and kidney.
An important issue in the analysis of rare variant association studies is the ability to annotate nonsynonymous variants in terms of their likely importance as affecting protein function. To address this, AlphaMissense was recently released and was shown to have good performance using benchmarks based on variants causing severe disease and on functional assays. Here, we assess the performance of AlphaMissense across 18 genes which had previously demonstrated association between rare coding variants and hyperlipidaemia, hypertension or type 2 diabetes. The strength of evidence in favour of association, expressed as the signed log p value (SLP), was compared between AlphaMissense and 43 other annotation methods. The results demonstrated marked variability between genes regarding the extent to which nonsynonymous variants contributed to evidence for association and also between the performance of different methods of annotating the nonsynonymous variants. Although AlphaMissense produced the highest SLP on average across genes, it produced the maximum SLP for only 4 genes. For some genes, other methods produced a considerably higher SLP and there were examples of genes where AlphaMissense produced no evidence for association while another method performed well. The marked inconsistency across genes means that it is difficult to decide on an optimal method of analysis of sequence data. The fact that different methods perform well for different genes suggests that if one wished to use sequence data for individual risk prediction then gene-specific annotation methods should be used.
OBJECTIVE: To evaluate the efficacy of sentinel lymph node biopsy (SLNB) in cT1/2N0 minor salivary gland cancer (mSGC) located within the oral cavity.
METHODS: A retrospective analysis was conducted on patients diagnosed with cT1/2N0 oral mSGC, who were categorized into two groups based on neck management approaches. The impact of SLNB versus observation on regional control and overall survival was assessed using a Cox model.
RESULTS: A total of 177 patients were included in the study, with 53 cases undergoing SLNB. All patients had at least one sentinel lymph node, with the majority having two sentinel lymph nodes. The sentinel lymph nodes were predominantly situated in level I, followed by level II. Four patients had positive sentinel lymph nodes, all of whom had primary tumors in the tongue or the floor of the mouth, and were classified as cT2 stage. This yielded a sensitivity and specificity of 100%, a false negative rate of 0%, and a negative predictive value of 100% for SLNB in predicting occult metastasis. In terms of regional control, SLNB exhibited a reduced hazard ratio of 0.90 (95% confidence interval: 0.64-0.96) compared to observation. However, SLNB did not confer a superior overall survival benefit compared to observation.
CONCLUSION: In patients with cT1/2N0 oral mSGC, SLNB proved to be both technically feasible and oncologically safe. When contrasted with observation, SLNB was associated with enhanced regional control, particularly recommending its use for cases of cT2 mSGC arising from the tongue or the floor of the mouth.
The invention belongs to the technical field of processing of Chinese herbal medicines and discloses a stasis eliminating and swelling relieving medicine. The medicine is prepared from calamint, radix paeoniae alba, rapeseeds, herba clinacanthi nutantis, herba clinopodii confinis, selenitum glanberitum, herba lamii amplexicaulis, semen artemisiae ordosicae, brown sugar, EM original liquid and the like. Calamint has efficacies of wind dispelling, heat clearing, detoxifying and swelling relieving; rapeseeds have efficacies of blood circulation promoting, stasis removing, swelling relieving and stagnation eliminating; herba clinopodii confinis and herba lamii amplexicaulis have efficacies of wind dispelling, heat clearing, Qi promoting, blood circulation promoting, meridian activating, detoxifying and swelling relieving; radix paeoniae alba has efficacies of Yang inhibiting, liver calming, Yin-Yang balancing, heat toxin and pathogenic factor eliminating and blood circulation promoting. By compatibility of the herba clinopodii confinis and herba lamii amplexicaulis, medicinal healing is promoted, and satisfying treatment effects can be achieved quickly. Semen artemisiae ordosicae which serves as a binding agent has efficacies of wind dispelling, damp eliminating, heat clearing, detoxifying and swelling relieving. By combination of brown sugar and EM original liquid, excellent effects of EM original liquid can be enhanced. Functional diversification is realized, efficacies of the medicine are greatly improved, and quality of the medicine is improved as well.
312,253. Dehn, F. B., (Chemische Pharmazeutische Akt.-Ges. Bad Homburg). Feb. 21, 1928. Hypodermic injections.-Aqueous solutions of quinine base, suitable for injection, are prepared by dissolving the quinone base in a solution of quinine salt. The PH value may be adjusted to that of the blood. (7.4) or that of the tissue (7.2). Examples are given in which the quinine salts used are hydrochloride, formate, and lactate respectively. Larger quantities of quinone base may be held in solution, or solutions capable of further dilution with water may be obtained, by adding 1.phenyl.2.3.dimethyl.5.pyrazolone, isovaleramide, or urethane in addition to the quinine salt,
PROBLEM TO BE SOLVED: To obtain the subject composition by formulating plant extract(s) as active ingredient. SOLUTION: This composition, which is intended to promote tyrosinase activity, is obtained by formulating, as active ingredient, at least one kind of extract derived from plant belonging to the genus Apocynaceae Rauvolfia (e.g. Pule pandak). This composition may contain an ingredient (e.g. swertia extract, carrot extract) usable as a hair tonic ingredient. This composition has only to be in such a form as to be applicable to the skin or scalp such as a liquid, milky lotion or ointment, being in the form of emollient lotion, emollient cream, moisture gel, etc. The optimum content of the extract in the composition is pref. 0.01-5 wt.% on a dry basis. When this composition is to be applied to the scalp, the daily dose of the active ingredient is e.g. 0.1-80 mg/adult each time.
Vibration devices have been used by some patients with cerebral palsy during therapy sessions. Researchers believe they have the potential to be even more useful for everyday use, and are doing this study to learn more about what they can do.

Participate in this study will be asked to complete assessments that test arm motion, muscle tone, motor control, and sensory function. They will then be asked to wear a wristband on each wrist and on their shoulder. These wristbands contain vibrators that can vibrate at different levels. The vibrations are caused by a low-level of sound waves that people may barely be able to hear. While wearing the vibration devices on the wrist and shoulder, participants will be asked to perform two tasks. The first task is called the box and blocks test, which consists of transferring wooden blocks from one box to another. The second test is called the Shriners upper extremity evaluation (SHUEE). In this test participants will perform a series of fine motor tasks with their hands. The SHUEE test will be video recorded for scoring by a study therapist at a later time on how much and how well participants use their impaired arm to perform the tasks. Participants will be asked to complete the box and blocks test and the SHUEE test 3 times. Participation in this study will be one single visit and last approximately an hour to an hour and a half.
PURPOSE: We aim to compare the different treatment modalities of non-tuberculous cervicofacial lymphadenitis in children, by means of a retrospective study conducted in the University Hospitals of Leuven of patients treated between 2012 and 2022.
METHODS: For this retrospective cohort study, data were collected and pseudonimised from 52 patients with non-tuberculous cervicofacial lymphadenitis, who were treated in our hospital between January 2012 and December 2022, either conservatively, antibiotically, surgically, or with a combination of these options. We only included patients who were considered immunocompetent. All of the included patients were below 10 years at time of treatment. We collected data regarding time to resolution and adverse effects, i.e., skin discoloration, excessive scar formation, fistula formation, persistence of adenopathies after treatment, need for additional treatment, facial nerve paresis/paralysis, or systemic side-effects due to antibiotic treatment.
RESULTS: The mean time to resolution (in days) when looking at primary treatments, was shortest in partial excisions (16), followed by complete excisions (19), antibiotic therapy (129), incision and drainage (153), curettage (240), and finally conservative management (280). Taking into account isolated treatments (i.e., both primary and adjuvant), we also observed consistently faster time to resolution in surgical and antibiotic treatments when compared to conservative treatment. Antibiotic therapy (p = 0.003), incision and drainage (p = 0,004) were associated with a significantly higher need for adjuvant treatment. Curettage was associated with a higher incidence of fistula formation (p = 0,006) and higher number of adjuvant treatments (p = 0,002).
CONCLUSIONS: This study shows a faster resolution of nontuberculous mycobacterial cervicofacial lymphadenitis in children when treated surgically, more specifically when treated with partial or complete lymph node excision. Antibiotic treatment also leads to faster resolution than conservative management. There was a low rate of complications, and no permanent facial nerve damage was reported.
The invention discloses a tofacitinib sustained-release preparation and a preparation method thereof. The tofacitinib sustained-release preparation according to the present invention comprises a drug-containing tablet core and a sustained-release coating, wherein the drug-containing tablet core comprises tofacitinib bulk drug, filler, excipient, disintegrant, binder, and lubricant. The sustained-release coating comprises a coating -forming material and a pore-forming agent. The disintegrant comprises sodium carboxymethyl starch. The tofacitinib sustained-release preparation according to the present invention can reduce the food effect, achieving the sustained-release effect. Meanwhile, the treatment effect can be achieved by taking the medicine once a day, being biologically equivalent to the commercially available preparation.
Sedation of intensive care patients is needed for patient's safety but deep sedation is associated with adverse outcomes. Frontal electromyogram based Responsiveness Index (RI) aims to quantify patient's arousal. RI monitoring together with staff education may have potential to improve sedation quality. Investigators will evaluate the safety of RI based sedation versus standard care using Richmond Agitation-Sedation Scale (RASS) for sedation.

Methods: randomized study, critically ill adult patients with mechanical ventilation and administration of sedation to either RI- or RASS-guided sedation. Propofol (and midazolam combined with if needed) as a hypnotic drug and oxycodone as an analgesic drug. Investigators will follow standardized sedation protocol in both groups to achieve the predetermined target sedation level: either RI 40-80 (RI-group) or RASS -3-0 (RASS group). RI measurement is continuous in both groups, but blinded in the RASS group. Accordingly, RI group is blinded to RASS assessments. State Entropy (SE) will register in both groups.